Mustang Bio Inc (MBIO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.52 (+5.17%), Market cap $0.00B, 52-week low–high $0.61 ~ $3.34.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic vir
Financial statements, price targets, institutional (13F) holdings and related news for Mustang Bio Inc are updated in real time on BlackAll Trade.
Mustang Bio Inc trades at $0.52 (+5.17%). Real-time quotes and charts are available on BlackAll Trade.
Mustang Bio Inc has a market cap of about $0.00B.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company